Clinical data for Moderna’s COVID-19 vaccine showed it was nearly 95% effective in preventing disease, according to an interim analysis described in a company release Monday.

CAMBRIDGE, MASSACHUSETTS – MAY 08: A view of Moderna headquarters on May 08, 2020 in Cambridge, Massachusetts. Moderna was given FDA approval to continue to phase 2 of Coronavirus (COVID-19) vaccine trials with 600 participants. (Photo by Maddie Meyer/Getty Images)